Title |
Intratumoral distribution of EGFR mutations and copy number in metastatic lung cancer, what impact on the initial molecular diagnosis?
|
---|---|
Published in |
Journal of Translational Medicine, May 2014
|
DOI | 10.1186/1479-5876-12-131 |
Pubmed ID | |
Authors |
Audrey Mansuet-Lupo, Fouzia Zouiti, Marco Alifano, Anne Tallet, Marie-Christine Charpentier, Véronique Ducruit, Fabrice Devez, Fanny Lemaitre, Pierre Laurent-Puig, Diane Damotte, Hélène Blons |
Abstract |
Activating epidermal growth factor receptor (EGFR) mutations characterize a subgroup of non-small-cell lung cancer that benefit from first line EGFR tyrosine kinase inhibitors (EGFR-TKI). However, the existence of polyclonal cell populations may hinder personalized-medicine strategies as patients' screening often depends upon a single tumor-biopsy sample. The purpose of this study is to clarify and to validate in clinical testing conditions the accuracy of EGFR genotyping using different tumor sites and various types of samples (transthoracic, surgical or endoscopic biopsies and cytology specimens). |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Serbia | 1 | 3% |
Unknown | 28 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 6 | 21% |
Researcher | 4 | 14% |
Other | 3 | 10% |
Professor | 3 | 10% |
Student > Master | 2 | 7% |
Other | 3 | 10% |
Unknown | 8 | 28% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 7 | 24% |
Biochemistry, Genetics and Molecular Biology | 7 | 24% |
Agricultural and Biological Sciences | 2 | 7% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 3% |
Chemistry | 1 | 3% |
Other | 0 | 0% |
Unknown | 11 | 38% |